solute carrier family 22 member 3Genealiases: EMT · EMTH · OCT3
Q-omics provides the consensus-scored SLC22A3 profile across patient tissues and cancer cell-line models. SLC22A3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC22A3 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, SLC22A3 RNA expression shows 21,434 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, COAD, and LSCC as cancer lineages where SLC22A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC22A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC22A3 survival associations across molecular data types. SLC22A3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC22A3 RNA expression–survival associations across cancer types. High SLC22A3 expression shows unfavorable associations in ACC, CESC, OV, LUSC and MESO, but favorable associations in COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC22A3 RNA expression.
This table summarizes SLC22A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC22A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC22A3 shows lower tumor expression in KICH, BLCA, LUAD, THCA and LUSC and higher tumor expression in COAD. The COAD box plot shows higher SLC22A3 RNA expression in tumor versus normal tissue (log2 FC = +1.814, t-test p < 0.001).
This table shows molecular features associated with SLC22A3 in patient tissues and cancer cell lines. In patient samples, SLC22A3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC22A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
